Middle East & Africa Ovarian Cancer Diagnostics And Therapeutics Market Size

MEA Ovarian Cancer Diagnostics & Therapeutics Market Analysis

The Middle East & Africa Ovarian Cancer Diagnostics And Therapeutics Market size is estimated at USD 244.60 million in 2024, and is expected to reach USD 357.73 million by 2029, growing at a CAGR of 7.90% during the forecast period (2024-2029).

The COVID-19 pandemic impacted the growth of the Middle East and African cancer diagnostics and therapeutics market. For instance, an article published by the National Centre for Biotechnology Information (NCBI) in May 2022 reported that the COVID-19 pandemic has disrupted cancer care to a certain degree in Saudi Arabia. The article also reported that women with ovarian cancer had disruptions in their treatment plans during COVID-19 due unavailability of proper ovarian cancer diagnostics in the country, as a result of the growth of the studied market being hampered due to COVID-19. In the current scenario, it is expected that with the decrease in COVID-19 cases and ease in restriction, diagnostics services may resume in the country. Thus, the studied market is expected to witness growth over the forecast period.

The major factors that are responsible for the growth of the market include the growing burden of ovarian cancer and the use of combination therapies for the treatment of ovarian cancer. An article published by the American Society of Clinical Oncology Journal in March 2022 reported that, of 463,675 new cancer cases estimated to be in Arab countries, 5.2% of the total cancers accounted for ovarian cancers. Similarly, another article published by NCBI in April 2022 reported that the prevalence of ovarian cancer in South Africa was 4.9% in the year 2020-2021. Thus, the high prevalence of ovarian cancer is increasing the demand for ovarian cancer diagnostics and therapeutics in the MENA region, thereby driving the growth of the studied market.

Also, another article published by the Saudi Pharmaceutical Journal in January 2023 reported that in Saudi Arabia, according to the National Cancer Registry, ovarian cancer is the seventh most common cancer, representing 3.3 % of the total cancers affecting women. The article also quoted that ovarian cancer is the 10th most lethal cancer among several other cancers as per the latest data from the International Agency for Research on Cancer. Thus, such instances are driving the demand for diagnostics and therapeutics for the studied market.

Furthermore, technological developments and new product launches are expected to drive the growth of the studied market. For instance, in February 2023, United Imaging, a global innovator in cutting-edge medical imaging and radiotherapy equipment, attended Arab Health 2023 as a Platinum partner in Dubai, UAE, with a broad range of state-of-the-art medical imaging devices, including HD TOF PET/MR uPMR 790; cardiac CT, the ultra-fast high-resolution digital PET/CT uMI 780; the newly launched uAiFI-powered 1.5T Wide Bore MRI System with "3T-like" performance, the uMR 680; and the most compact mobile DR system, uDR 380i Pro. Thus,

Thus, the growing burden of ovarian cancer and the new product launches are driving the growth of the studied market. However, a lack of awareness in emerging and low-income economies is slowing down the growth of the studied market.